Recent Updates — OPK
OPKO Health and its subsidiary BioReference entered into an Asset Purchase Agreement with Laboratory Corporation of America Holdings (LabCorp) to sell the clinical and anatomic pathology laboratory testing business. The transaction includes assets focused on women's health, urology, corrections, and the proprietary 4Kscore prostate cancer test. LabCorp will pay $722 million in cash at closing, subject to revenue adjustments, plus up to $150 million over ten years based on future sales of the 4Kscore test. The deal is not subject to financing conditions but requires Hart-Scott-Rodino clearance and customary closing conditions, with a termination fee of approximately $28.9 million if approvals fail. OPKO Health operates in the healthcare diagnostics and clinical laboratory services industry.
OPKO Health announced that its $121 million outstanding Convertible Senior Notes due 2029 have become convertible through December 31, 2026. The conversion right was triggered because the common stock closing price exceeded $1.495 (130% of the $1.15 conversion price) for at least 20 of 30 consecutive trading days in the quarter ended September 30, 2026. The company elected to settle conversions in shares rather than cash. Convertible holders will receive approximately 869.57 shares per $1,000 principal amount plus additional shares for early conversion. OPKO Health operates in the biotechnology and diagnostics industry.
OPKO Health, Inc. entered into an amendment to its Note Purchase Agreement on August 13, 2026, issuing $125 million in additional senior secured notes maturing July 17, 2044. Interest accrues at SOFR plus 7.5% with a 4.0% floor and is payable quarterly using profit share payments from EirGen Pharma’s Pfizer arrangement for mazdutide sales in China. If those royalties are insufficient, interest is paid from Mazdutide Payments secured by an Eli Lilly license, capped at $187.5 million, with any excess applied to principal reduction. The company operates in the biotechnology and healthcare diagnostics industry.
OPKO Health, Inc. reported second quarter 2026 financial results, with consolidated total revenues of $163.5 million compared to $156.8 million in the prior year period. The company's operating loss for the second quarter was $7.0 million, an improvement from a $60.0 million operating loss in the same period in 2025. Net loss per share of $0.01 per share was reported for the second quarter. OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company focused on delivering next-generation solutions for serious diseases across global markets.